Mizuho Securities Remains Bullish on Eagle Pharmaceuticals (EGRX) Despite Weak 4Q; Investors Focus on Bendeka Opportunity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. ROIV
6. AAPL
7. HOOD
8. QCOM
9. ACN
10. AZN

Go back to Mizuho Securities Remains Bullish on Eagle Pharmaceuticals (EGRX) Despite Weak 4Q; Investors Focus on Bendeka Opportunity

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2015 Results

February 25, 2016 6:50 AM EST

-Eagle Achieves Full Year 2015 Net Income of $0.16 Per Diluted Share-

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced its financial results for the three- and twelve-month periods ended December 31, 2015. Highlights of and subsequent to the fourth quarter of 2015 include:

Business Highlights:

Received approval from the U.S. Food and Drug Administration (FDA) of BENDEKA, triggering a $15 million milestone payment from Teva Pharmaceutical Industries Ltd. The Company will receive a 20% royalty on net sales of BENDEKA, which... More